PTC Theraputics Inc. shares fell in the extended session Thursday after the biotech said a muscular dystrophy treatment did not reach its primary endpoint in a late-stage clinical study. PTC shares dropped 17% to $26.49 on heavy volume. The company said a Phase 3 study of its treatment Translarna did not reach its primary endpoint of improving walking test scores in certain MD patients on a statistically significant basis.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
From:: Stock Market News